Financial giants have made a conspicuous bearish move on Apellis Pharmaceuticals. Our analysis of options history for Apellis Pharmaceuticals APLS revealed 15 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $496,047, and 6 were calls, valued at $511,853.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $75.0 for Apellis Pharmaceuticals, spanning the last three months.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Apellis Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Apellis Pharmaceuticals's significant trades, within a strike price range of $40.0 to $75.0, over the past month.
Apellis Pharmaceuticals Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APLS | CALL | TRADE | NEUTRAL | 08/16/24 | $7.8 | $5.0 | $6.5 | $45.00 | $162.5K | 0 | 6.7K |
| APLS | CALL | SWEEP | BEARISH | 05/17/24 | $2.35 | $1.3 | $2.3 | $45.00 | $106.5K | 254 | 1.5K |
| APLS | CALL | SWEEP | BEARISH | 05/17/24 | $4.7 | $3.6 | $3.6 | $45.00 | $90.0K | 254 | 500 |
| APLS | PUT | SWEEP | BEARISH | 06/21/24 | $3.3 | $3.1 | $3.2 | $40.00 | $84.8K | 107 | 147 |
| APLS | PUT | SWEEP | BULLISH | 05/17/24 | $9.1 | $8.1 | $8.7 | $50.00 | $78.3K | 334 | 16 |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Having examined the options trading patterns of Apellis Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Where Is Apellis Pharmaceuticals Standing Right Now?
- With a volume of 4,136,096, the price of APLS is down -8.19% at $43.92.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 7 days.
Expert Opinions on Apellis Pharmaceuticals
5 market experts have recently issued ratings for this stock, with a consensus target price of $74.2.
- In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $85.
- An analyst from Mizuho has decided to maintain their Neutral rating on Apellis Pharmaceuticals, which currently sits at a price target of $52.
- An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $85.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $92.
- An analyst from Wedbush has decided to maintain their Neutral rating on Apellis Pharmaceuticals, which currently sits at a price target of $57.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Apellis Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
